July - September 2024

• Net asset value was SEK 4,262 million (3,212) and net asset value per share was SEK 54.59 (52.88), adjusted net asset value per share was SEK 55.91 (52.88)
• Change in net asset value per share in the quarter was -2.7 per cent (-8.5)
• Total fair value of shares in portfolio companies was SEK 2,993 million (2,939)
• Change in fair value of shares in portfolio companies was SEK -121 million (-302), equivalent to -4.0 per cent (-9.9)
• Net profit/loss amounted to SEK -117 million (-299)
• Earnings per share before and after dilution amounted to SEK -1.50 (-4.92)

January - September 2024

• Change in net asset value per share was -7.0 per cent (-5.4), adjusted change in net asset value per share was -4.8 per cent
• Change in fair value of shares in portfolio companies was SEK -102 million (-299), equivalent to -3.6 per cent (-11.0).
• Net profit/loss amounted to SEK -164 million (-301)
• Earnings per share before and after dilution amounted to SEK -2.42 (-6.62)
• The expense ratio amounted to 1.3 per cent (1.4)
• Cash and cash equivalents amounted to SEK 911 million (310)

Significant events during the quarter

• Flerie has carried out a reverse share split of 1:100, whereby 100 existing shares became 1 share, with the record date 15 July 2024.
• Flerie increased its shareholding in Xspray Pharma and commented on FDA feedback on Dasynoc.

Shareholders, financial analysts and media are kindly invited to a webcast in English, including presentation of the quarterly results and a Q&A, today on the 16th of October 2024 at 11:00 CET.

If you wish to participate via webcast please register via the link below. Please note that it can take a few minutes to receive the confirmation e-mail with the Teams link following registration: https://events.teams.microsoft.com/event/ef8fe4b3-cc62-47ab-addd-f56de753bdff@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2

The presentation will be available after the webcast at www.flerie.com